Skolnick Sarah, Brouwer Andrew, Cheng Charlene, Tam Jamie
Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, United States.
Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States.
medRxiv. 2025 Jul 11:2025.07.10.25331302. doi: 10.1101/2025.07.10.25331302.
The U.S. FDA has proposed a product standard that would reduce the nicotine content and addictiveness of cigarettes. It is unclear what impact this would have on economic outcomes or priority populations who are disproportionately harmed by tobacco use, such as people with major depression.
To evaluate the long-term health and economic impacts of a nicotine product standard for the U.S. population by depression status.
A microsimulation model was developed and calibrated to National Survey on Drug Use and Health (NSDUH) 2005-2023 data on smoking, vaping, and depressive episodes. The anticipated effects of the nicotine product standard on smoking and vaping were obtained from an FDA expert elicitation and used to simulate the policy from 2027-2100.
Smoking and vaping.
Health outcomes included prevalence of smoking and vaping, deaths, and life years gained overall and by major depression status. Economic outcomes include direct costs to the healthcare system and societal costs.
Under the proposed nicotine product standard, smoking is projected to decline to <1% for people with and without depression by 2100. The policy is estimated to avert 1.7 million premature deaths and lead to 74.7 million life years gained. Depression prevalence is also expected to decline, with 8.5 million fewer cases of depression estimated. Longer life expectancies under the policy are projected to increase medical costs by $296 billion, while also increasing worker productivity by $266 billion with an additional $1.2 trillion in consumer spending.
Timely implementation of a nicotine reduction strategy, either through a federal product standard or state-level sales restrictions, is cost-effective and could prevent millions of premature deaths and reduce smoking disparities by depression status.
美国食品药品监督管理局(FDA)提议了一项产品标准,该标准将降低香烟中的尼古丁含量和成瘾性。目前尚不清楚这将对经济成果或受烟草使用影响尤为严重的优先人群(如重度抑郁症患者)产生何种影响。
按抑郁状态评估尼古丁产品标准对美国人群的长期健康和经济影响。
设计、背景与参与者:开发了一个微观模拟模型,并根据2005 - 2023年全国药物使用和健康调查(NSDUH)中关于吸烟、吸电子烟和抑郁发作的数据进行校准。尼古丁产品标准对吸烟和吸电子烟的预期影响来自FDA专家的意见,并用于模拟2027年至2100年的政策。
吸烟和吸电子烟。
健康结局包括吸烟和吸电子烟的患病率、死亡人数以及总体和按重度抑郁状态计算的获得的生命年数。经济结局包括医疗系统的直接成本和社会成本。
根据提议的尼古丁产品标准,预计到2100年,无论是否患有抑郁症,吸烟率都将降至1%以下。该政策预计可避免170万例过早死亡,并带来7470万个生命年的增加。抑郁症患病率预计也将下降,估计抑郁症病例减少850万例。预计该政策下更长的预期寿命将使医疗成本增加2960亿美元,同时使工人生产力提高2660亿美元,消费者支出额外增加1.2万亿美元。
通过联邦产品标准或州级销售限制及时实施尼古丁减少策略具有成本效益,可预防数百万例过早死亡,并减少因抑郁状态导致的吸烟差异。